Atossa Therapeutics’ (ATOS) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Atossa Therapeutics (NASDAQ:ATOS) in a research note issued to investors on Tuesday morning, Marketbeat.com reports. They currently have a $4.00 price objective on the stock.

Other equities analysts have also issued research reports about the company. StockNews.com lowered Atossa Therapeutics from a hold rating to a sell rating in a report on Monday, March 18th. Cantor Fitzgerald reissued an overweight rating on shares of Atossa Therapeutics in a report on Friday, January 12th.

Atossa Therapeutics Stock Performance

ATOS opened at $1.42 on Tuesday. The business’s 50-day simple moving average is $1.38 and its 200-day simple moving average is $0.98. Atossa Therapeutics has a one year low of $0.59 and a one year high of $2.31. The stock has a market capitalization of $177.93 million, a P/E ratio of -5.92 and a beta of 1.20.

Atossa Therapeutics (NASDAQ:ATOS) last released its quarterly earnings results on Monday, April 1st. The company reported ($0.06) earnings per share (EPS) for the quarter. On average, equities research analysts forecast that Atossa Therapeutics will post -0.28 EPS for the current fiscal year.

Insider Buying and Selling at Atossa Therapeutics

In other Atossa Therapeutics news, Director Jonathan Finn acquired 25,000 shares of the stock in a transaction on Wednesday, April 10th. The shares were bought at an average price of $1.77 per share, with a total value of $44,250.00. Following the acquisition, the director now owns 25,000 shares of the company’s stock, valued at $44,250. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 7.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Atossa Therapeutics

Several institutional investors have recently modified their holdings of ATOS. JPMorgan Chase & Co. boosted its stake in shares of Atossa Therapeutics by 27.0% during the 1st quarter. JPMorgan Chase & Co. now owns 54,960 shares of the company’s stock worth $69,000 after acquiring an additional 11,683 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Atossa Therapeutics by 4.8% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 313,912 shares of the company’s stock worth $393,000 after purchasing an additional 14,481 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Atossa Therapeutics by 79.5% during the 1st quarter. Renaissance Technologies LLC now owns 2,100,492 shares of the company’s stock worth $2,626,000 after purchasing an additional 930,152 shares during the last quarter. State Street Corp raised its position in shares of Atossa Therapeutics by 4.2% during the 1st quarter. State Street Corp now owns 2,233,010 shares of the company’s stock worth $2,791,000 after purchasing an additional 90,960 shares during the last quarter. Finally, First Republic Investment Management Inc. raised its position in shares of Atossa Therapeutics by 79.8% during the 1st quarter. First Republic Investment Management Inc. now owns 25,167 shares of the company’s stock worth $31,000 after purchasing an additional 11,167 shares during the last quarter. Hedge funds and other institutional investors own 12.74% of the company’s stock.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.